DAVID STIER M.D.
Prescription History 1821197849
Pediatrics in San Francisco, CA

NPI Status: Active since September 22, 2006

Contact Information

101 GROVE ST
SUITE 204
SAN FRANCISCO, CA
ZIP 94102
Phone: (415) 554-2648

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DAVID STIER M.D., an active Pediatrics specialist practicing in San Francisco, CA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 235 documented patient claims. Among these therapy options, the most frequently utilized medication is Azithromycin, which accounts for 133 claims alone.

Medication Index

No matching medications currently found on file.

Atovaquone-Proguanil Hcl

Generic Formulation: Atovaquone/Proguanil HclSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 89
30-Day Fills 97.4
Days Supply 2,080
CA State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills65.4
Peer Average Days Supply1,544
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.8% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,603.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$85.44

State Avg Cost Per Claim

$103.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: atovaquone and proguanil. It is used to prevent and treat malaria caused by mosquito bites in countries where malaria is common. Malaria parasites can enter the body through these mosquito bites, and then live in body tissues such as red blood cells or the liver. This medication is used to kill the malaria parasites living inside red blood cells and other tissues. In some cases, you may need to take a different medication (such as primaquine) to complete your treatment. Both medications may be needed for a complete cure and to prevent the return of infection (relapse). Atovaquone/proguanil belongs to a class of drugs known as antimalarials. The United States Centers for Disease Control provide updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 133
30-Day Fills 133.0
Days Supply 450
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.6
Peer Average Days Supply270
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 250.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $592.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.46

State Avg Cost Per Claim

$7.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Ciprofloxacin Hcl

Generic Formulation: Ciprofloxacin HclSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 45
CA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.9
Peer Average Days Supply258
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $56.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.34

State Avg Cost Per Claim

$7.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A broad-spectrum antimicrobial carboxyfluoroquinoline.

Therapeutic Applications

This medication is used to treat eye infections. Ciprofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DAVID STIER M.D. provides transparency into local medical care patterns within San Francisco, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pediatrics** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.